Recombinant vhs-defective herpes simplex virus; for use as a vaccine

Recombinant vhs-defective herpes simplex virus; for use as a vaccine

Elsevier Vaccine, Vol. 15, No. 1, p. 105, 1997 Elsevier Sc’?nce Ltd Printed in Great Britain 0264-410X/97 $17+0.00 ELSEVIER Patent Report This sect...

166KB Sizes 0 Downloads 9 Views


Vaccine, Vol. 15, No. 1, p. 105, 1997 Elsevier Sc’?nce Ltd Printed in Great Britain 0264-410X/97 $17+0.00


Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from ‘Derwent Biotechnology Abstracts’ with permission of Derwent Information Ltd., Derwent House, 14 Great Queen Street, London, WC2B 5DF. Replication of hepatitis C virus in vitro; in monkey kidney or human fibroblast cell culture in serum-free medium for vaccine production CNR World 9624 662; 15 August 1996 A method to replicate the hepatitis C virus (HCV) in non lymphoblastoid mammalian cell culture (preferably monkey kidney or human fibroblast cell culture) is claimed, which involves: (a) incubating a HCV sample with the cells for a sufficient time to allow the adsorption of an infecting amount of HCV to occur; (b) washing out the infected cells; (c) incubating the HCV infected cells under suitable growth conditions; and (d) collecting the culture medium, preferably serum-free culture medium, and/or infected cells. Also claimed is a method as above, where the incubation step is replaced with an electroporation step. The culture medium or infected cell lyzate collected in step (d) is preferably recycled as the HCV sample for step (a). In an example, monkey kidney secondary cell culture in MEM medium with 2% fetal cattle serum was inoculated with HCV-infected serum diluted 15 in serum-free culture medium at 37 “C for 18 hr. The medium was removed and the cells were washed. The cells were then cultured in serum-free medium at 37 “C and HCV release was 066-96 detected up to 24 days after inoculation. Chimeric human rhinovirus with sequence encoding foreign antigen; influenza virus, polio virus-3, HIV virus-l, HIV virus-2, tumor, parasite or bacterium recombinant vaccine production using a human rhinovirus-14 vector Univ. New Jersey State USA 5541 100; 30 July 1996 A new chimeric human rhinovirus is constructed by insertion of a heterologous region into a human rhinovirus(HR14) neutralizing immunogenic site (e.g. Nlm-II viral protein VP2 amino acids 157-165 or NIm-IA viral protein VP1 amino acids 85-96) gene, so that the chimeric region is expressed on the HR14 surface, and participates in an immune reaction. The chimeric region may be from a neutralizing immunogenic site or a cellular receptor site, from an orthomyxo virus, e.g. influenza virus hemagglutinin antigen amino acids 128-136, a picornavirus, e.g. poliovirus-3 NAg-1 site amino acids 93-100, a retrovirus, e.g. HIV virus-l or HIV virus-2 gag or env protein, or non-viral origin, e.g. a tumor, parasite or bacterium. The chimeric virus is useful as a recombinant vaccine to generate an immune response against the immunogen, or to raise antibodies for use as diagnostic agents or for passive immunization. HR14 is only mildly pathogenic, has a wide serotypic diversity (reducing the likelihood of pre-existing immunity) and stimulates both mucosal and serum responses. 067-96 Recombinant vhs-defective herpes simplex virus; for use as a vaccine Univ. Washington, St. Louis World 9624 663; 15 August 1996 A recombinant herpes simplex virus (HSV) mutant UL41NHB, which is defective in virion host shutoff (vhs)

function, is claimed. The mutant is profoundly attenuated in its ability to replicate at the periphery and in the nervous system, and in its ability to reactivate from latency. It may be used for the development of HSV vaccines. In an example, a mutant virus, UL41NHB, was generated, which carries a nonsense linker inserted into the UL41 open reading frame. This mutant encoded a truncated form of vhs and failed to induce the degradation of glyceraldehyde-3-phosphatedehydrogenase (EC-l .2.1.12) mRNA. The growth of UL41NHB was compared to wild-type KOS and to vhsdelta-Sma, an in frame UL41 deletion mutant, and in contact-inhibited C3H/lOT1/2 mouse cells. The growth of vhs mutants was not significantly reduced in Vero cells, but was reduced by up to lOO-fold in C3H/lOT1/2 cells, indicating a significant impairment of growth in contact-inhibited cells. 068-96 Nucleotide and amino acid sequence of tumor gene; Int6 gene purification and isolation for cancer immunotherapy, diagnosis, vaccine development and gene therapy U.S. Dep. Health Hum. Serv. World 9624 672; 15 August 1996 A purified and isolated Int6 gene is new, containing a specified 1500 bp DNA sequence. Also claimed are: cDNA ATCC 97029 and ATCC 97030 encoding the Int6 gene; an Int6 gene-encoded protein with a specified protein sequence of 396 amino acids; a method (reverse transcription-polymerase chain reaction-single strand conformation polymorphism, Southern and Northern blot hybridization) for assaying a sample using one or more Int6 gene-derived nucleotide sequences; a method for assaying a sample using an Int6-specific monoclonal antibody; a recombinant expression vector containing the DNA sequence; a vaccine containing the vector; and a host cell transformed or transfected with the above vector. The compositions containing the vector and recombinant Int6 protein may be used for cancer immunotherapy and the Int6 gene is of use in diagnostic methods, vaccines and gene therapy. 069-96 New tumor rejection antigen precursor and gene; used to develop products for the diagnosis and treatment of disorders characterized by the TRAP, particularly melanoma Ludwig Inst. Cancer Res. World 9625 511; 22 August 1996 An isolated nucleic acid molecule (NAM) is claimed which consists of a specified sequence. Also claimed are: i. an isolated NAM which hybridizes to a specified NAM and which codes for a tumor rejection antigen (TRA) precursor (TRAP), where the isolated NAM does not code for a MAGE TRAP; ii. an isolated molecule complementary to a NAM as in (i.) where the molecule is mRNA or DNA; iii. a host cell transfectedl transformed with a NAM; iv. an expression vector comprising an isolated NAM operably linked to a promoter; v. an expression kit comprising a separate portion of each of an isolated NAM as above and an NAM which codes for HLA -Cw+1601; vi. a method for treating a disorder characterized by the presence of complexes of HLA molecules and the peptide with the sequence (I) on cell surfaces; vii. a method for diagnosing a disorder characterized by the presence of complexes of HLA molecules and the peptide (I) on cell surfaces. The TRAP and DNA encoding it were identified using the M22-MEL melanoma cell line. The products and methods can be used in the diagnosis and treatment of disorders characterized by expression of TRAP molecule (termed BAGE), 070-96 particularly melanoma.

Vaccine 1997 Volume 15 Number 1